JAK2 and rheumatoid arthritis: Tofacitinib, an effective oral JAK2/1/3 inhibitor, and baricitinib, a selective JAK1/JAK2 inhibitor, were approved by the FDA for the treatment of rheumatoid arthritis (RA) and ulcerative colitis(UC).